Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ASPIRE Study: A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy, for the Treatment of Pediatric Females Aged >2 to <4 Years With Rett Syndrome

NCT07480564 is registered in ClinicalTrials.gov with Taysha Gene Therapies, Inc. as lead sponsor.

NCT NCT07480564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07480564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ASPIRE Study: A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy, for the Treatment of Pediatric Females Aged >2 to <4 Years With Rett Syndrome
Lead sponsor
Taysha Gene Therapies, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 8, 2026
Completion date
June 30, 2031
Enrollment
4 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

rett syndrome